1-3 of 3
Marion Wiesmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma

Suzanne Trudel, Zhi Hua Li, Ellen Wei, Marion Wiesmann, Hong Chang, Christine Chen, Donna Reece, Carla Heise, A. Keith Stewart
Journal: Blood
Blood (2005) 105 (7): 2941–2948.
https://doi.org/10.1182/blood-2004-10-3913
Published: 2005
Journal Articles

CHIR258, a Novel Multi-Targeted Tyrosine Kinase Inhibitor, for the Treatment of t(4;14) Multiple Myeloma.

Suzanne Trudel, M.D., M.Sc., Zhi Hua Li, M.D., Ellen Wei, M.Sc., Marion Wiesmann, Ph.D., Katherine Rendahl, Ph.D., Eddie Moler, Ph.D., Chris Chen, M.D., Donna Reece, M.D., Joesph Mikhael, M.D., Carla Heise, Ph.D., A. Keith Stewart, M.D.
Journal: Blood
Blood (2004) 104 (11): 641.
https://doi.org/10.1182/blood.V104.11.641.641
Published: 2004
Journal Articles

CHIR258: A Multitargeted Growth Factor Receptor Tyrosine Kinase (RTK) Inhibitor Induces Significant Apoptosis of Human FLT3 ITD Acute Myelogenous Leukemia Cells In Vitro and in Vivo.

Daniel L. Menezes, PhD, Marion Wiesmann, PhD, Sang Hoon Lee, PhD, Isabelle Lee, BS, Jing Peng, MS, Yan Tang, MD, Helen Ye, BS, Yoko Oei, BA, Cheryl Goldbeck, BS, Evelyn N. Garrett, MA, Carla Heise, PhD
Journal: Blood
Blood (2004) 104 (11): 1789.
https://doi.org/10.1182/blood.V104.11.1789.1789
Published: 2004